Top 5 Most Read RNS's on Vox Markets for Friday 30th September 2022
Episode 929, Sep 30, 2022, 07:27 AM
Top 5 Most Read RNS's on Vox Markets for Friday 30th September 2022
5. Nanosynth Group #NNN - Half-year Report
Successful trial results with Volz Holdings and REACH UK registration, Creating potential to lead to wider adoption by the global filtration industry & their pipeline of interest is already at an advanced stage.
4. Premier African Min #PREM - Half-year Report
The company provides further updates particularly in regard to Zulu Lithium Private Limited ("Zulu"). This includes:
Commencement of construction activities at site & Acceleration of assay results that should see an upgrade to the resource confidence level in the coming months.
3. Immupharma #IMM - Lupuzor Update
Further details on the next steps for Lupuzor™ will be communicated to the market, once finalised between ImmuPharma and Avion in after the complete response letter from the Food and Drug Administration ("FDA") to the Type C meeting.
2. Open Orphan #ORPH - Positive in vitro results for FLU-v published
Positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited's ("Imutex") broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1
1. Eurasia Mining #EUA - Interim Results for the six months ended 30 June
The first half of 2022 has seen significant progress at our West Kytlim mine & plan to install grid power to site to reduce the carbon output associated with overburden stripping, while also reducing operational expenditure and improving efficiency, is advancing well.
5. Nanosynth Group #NNN - Half-year Report
Successful trial results with Volz Holdings and REACH UK registration, Creating potential to lead to wider adoption by the global filtration industry & their pipeline of interest is already at an advanced stage.
4. Premier African Min #PREM - Half-year Report
The company provides further updates particularly in regard to Zulu Lithium Private Limited ("Zulu"). This includes:
Commencement of construction activities at site & Acceleration of assay results that should see an upgrade to the resource confidence level in the coming months.
3. Immupharma #IMM - Lupuzor Update
Further details on the next steps for Lupuzor™ will be communicated to the market, once finalised between ImmuPharma and Avion in after the complete response letter from the Food and Drug Administration ("FDA") to the Type C meeting.
2. Open Orphan #ORPH - Positive in vitro results for FLU-v published
Positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited's ("Imutex") broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1
1. Eurasia Mining #EUA - Interim Results for the six months ended 30 June
The first half of 2022 has seen significant progress at our West Kytlim mine & plan to install grid power to site to reduce the carbon output associated with overburden stripping, while also reducing operational expenditure and improving efficiency, is advancing well.